Cadrenal Therapeutics Overview
- Year Founded
-
2022
- Status
-
Public
- Employees
-
5
- Stock Symbol
-
CVKD
- Investments
-
2
- Share Price
-
$1.51
- (As of Friday Closing)
Cadrenal Therapeutics General Information
Description
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Contact Information
Website
www.cadrenal.comCorporate Office
- 822 North A1A
- Ponte Vedra Beach, FL 32082
- United States
Corporate Office
- 822 North A1A
- Ponte Vedra Beach, FL 32082
- United States
Cadrenal Therapeutics Timeline
Cadrenal Therapeutics Stock Performance
As of 13-Nov-2026, Cadrenal Therapeutics’s stock price is $1.51. Its current market cap is $5.39M with 3.57M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.51 | $1.51 | $0.82 - $12.50 | $5.39M | 3.57M | 479K | -$4.91 |
Cadrenal Therapeutics Financials Summary
As of 30-Jun-2026, Cadrenal Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 7,973 | 11,992 | 21,467 | 553 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (11,652) | (13,454) | (10,959) | (8,587) |
| Net Income | (11,544) | (13,237) | (10,651) | (8,357) |
| Total Assets | 5,589 | 4,327 | 10,124 | 8,519 |
| Total Debt | 0 | 0 | 0 | 21 |
Cadrenal Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cadrenal Therapeutics Comparisons
Industry
Financing
Details
Cadrenal Therapeutics Competitors (4)
One of Cadrenal Therapeutics’s 4 competitors is Arthrosi Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arthrosi Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| DiaMedica Therapeutics | Formerly VC-backed | Minneapolis, MN | ||||
| Ardelyx | Formerly VC-backed | Waltham, MA | ||||
| Akebia Therapeutics | Formerly VC-backed | Cambridge, MA |
Cadrenal Therapeutics Patents
Cadrenal Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025245618-A1 | Methods for treating heparin-induced thrombocytopenia | Pending | 27-Mar-2024 | ||
| AU-2025229087-A1 | Method for preventing coagulation in patients with implanted cardiac devices | Pending | 01-Mar-2024 | ||
| US-20250276120-A1 | Method for preventing coagulation in patients with implanted cardiac devices | Pending | 01-Mar-2024 | ||
| WO-2025184627-A1 | Method for preventing coagulation in patients with implanted cardiac devices | Pending | 01-Mar-2024 | ||
| US-20260048071-A1 | 12-lipoxygenase inhibitors for the treatment of lupus | Pending | 11-Nov-2022 | A61K31/63 |
Cadrenal Therapeutics Signals
Cadrenal Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cadrenal Therapeutics Investments & Acquisitions (2)
Cadrenal Therapeutics’s most recent deal was a Corporate Asset Purchase with Veralox Therapeutics (VLX-1005 and 12-Lipoxygenase Assets in Frederick, Maryland) for . The deal was made on 11-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Veralox Therapeutics (VLX-1005 and 12-Lipoxygenase Assets in Frederick, Maryland) | 11-Dec-2025 | Corporate Asset Purchase | Buildings and Property | ||
| eXIthera Pharmaceuticals | 15-Sep-2025 | Merger/Acquisition | Drug Discovery |
Cadrenal Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.59 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Cadrenal Therapeutics FAQs
-
When was Cadrenal Therapeutics founded?
Cadrenal Therapeutics was founded in 2022.
-
Where is Cadrenal Therapeutics headquartered?
Cadrenal Therapeutics is headquartered in Ponte Vedra Beach, FL.
-
What is the size of Cadrenal Therapeutics?
Cadrenal Therapeutics has 5 total employees.
-
What industry is Cadrenal Therapeutics in?
Cadrenal Therapeutics’s primary industry is Drug Discovery.
-
Is Cadrenal Therapeutics a private or public company?
Cadrenal Therapeutics is a Public company.
-
What is Cadrenal Therapeutics’s stock symbol?
The ticker symbol for Cadrenal Therapeutics is CVKD.
-
What is the current stock price of Cadrenal Therapeutics?
As of 13-Nov-2026 the stock price of Cadrenal Therapeutics is $1.51.
-
What is the current market cap of Cadrenal Therapeutics?
The current market capitalization of Cadrenal Therapeutics is $5.39M.
-
Who are Cadrenal Therapeutics’s competitors?
Arthrosi Therapeutics, DiaMedica Therapeutics, Ardelyx, and Akebia Therapeutics are competitors of Cadrenal Therapeutics.
-
What is Cadrenal Therapeutics’s annual earnings per share (EPS)?
Cadrenal Therapeutics’s EPS for 12 months was -$4.91.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process